Literature DB >> 27815111

Cross-Cultural Adaptation and Validation of the Spanish-Language Version of the SARC-F to Assess Sarcopenia in Mexican Community-Dwelling Older Adults.

Lorena Parra-Rodríguez1, Claudia Szlejf1, Ana Isabel García-González2, Theodore K Malmstrom3, Esteban Cruz-Arenas4, Oscar Rosas-Carrasco5.   

Abstract

OBJECTIVES: To cross-culturally adapt and validate the Spanish-language version of the SARC-F in Mexican community-dwelling older adults.
DESIGN: Cross-sectional analysis of a prospective cohort.
SETTING: The FraDySMex study, a 2-round evaluation of community-dwelling adults from 2 municipalities in Mexico City. PARTICIPANTS: Participants were 487 men and women older than 60 years, living in the designated area in Mexico City. MEASUREMENTS: Information from questionnaires regarding demographic characteristics, comorbidities, mental status, nutritional status, dependence in activities of daily living, frailty, and quality of life. Objective measurements of muscle mass, strength and function were as follows: skeletal muscle mass index (SMI) was taken using dual-energy x-ray, grip strength using a hand dynamometer, 6-meter gait speed using a GAIT Rite instrumented walkway, peak torque and power for knee extension using a isokinetic dynamometer, lower extremity functioning measured by the Short Physical Performance Battery (SPPB), and balance using evaluation on a foam surface, with closed eyes, in the Modified Clinical Test of Sensory Integration. The SARC-F scale translated to Spanish and the consensus panels' criteria from European, international, and Asian sarcopenia working groups were applied to evaluate sarcopenia.
RESULTS: The Spanish language version of the SARC-F scale showed reliability (Cronbach alfa = 0.641. All items in the scale correlated to the scale's total score, rho = 0.43 to 0.76), temporal consistency evaluated by test-retest (CCI = 0.80), criterion validity when compared to the consensus panels' criteria (high specificity and negative predictive values). The scale was also correlated to other measures related to sarcopenia (such as age, quality of life, self-rated health status, cognition, dependence in activities of daily living, nutritional status, depression, gait speed, grip strength, peak torque and power for knee extension, SPPB, balance, SMI, and frailty).
CONCLUSION: The SARC-F scale was successfully adapted to Spanish language and validated in community-dwelling Mexican older adults. Copyright Â
© 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SARC-F; Sarcopenia; dynapenia; frailty; validation

Mesh:

Year:  2016        PMID: 27815111     DOI: 10.1016/j.jamda.2016.09.008

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  34 in total

1.  Translation and Validation of the Spanish Version of the SARC-F Questionnaire to Assess Sarcopenia in Older People.

Authors:  D Sánchez-Rodríguez; E Marco; V Dávalos-Yerovi; J López-Escobar; M Messaggi-Sartor; C Barrera; N Ronquillo-Moreno; O Vázquez-Ibar; A Calle; M Inzitari; K Piotrowicz; X Duran; F Escalada; J M Muniesa; E Duarte
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Editorial: Screening for Sarcopenia.

Authors:  J E Morley; A M Sanford
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

3.  International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.

Authors:  E Dent; J E Morley; A J Cruz-Jentoft; H Arai; S B Kritchevsky; J Guralnik; J M Bauer; M Pahor; B C Clark; M Cesari; J Ruiz; C C Sieber; M Aubertin-Leheudre; D L Waters; R Visvanathan; F Landi; D T Villareal; R Fielding; C W Won; O Theou; F C Martin; B Dong; J Woo; L Flicker; L Ferrucci; R A Merchant; L Cao; T Cederholm; S M L Ribeiro; L Rodríguez-Mañas; S D Anker; J Lundy; L M Gutiérrez Robledo; I Bautmans; I Aprahamian; J M G A Schols; M Izquierdo; B Vellas
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

4.  Validation of the Italian Version of the SARC-F Questionnaire to Assess Sarcopenia in Older Adults.

Authors:  Simone Perna; Clara Gasparri; Cinzia Ferraris; Gaetan Claude Barrile; Alessandro Cavioni; Francesca Mansueto; Zaira Patelli; Gabriella Peroni; Alice Tartara; Marco Zese; Mariangela Rondanelli
Journal:  Nutrients       Date:  2022-06-18       Impact factor: 6.706

Review 5.  Prevalence of Undernutrition, Frailty and Sarcopenia in Community-Dwelling People Aged 50 Years and Above: Systematic Review and Meta-Analysis.

Authors:  Nada Almohaisen; Matthew Gittins; Chris Todd; Jana Sremanakova; Anne Marie Sowerbutts; Amal Aldossari; Asrar Almutairi; Debra Jones; Sorrel Burden
Journal:  Nutrients       Date:  2022-04-07       Impact factor: 6.706

6.  Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures.

Authors:  G Bahat; O Yilmaz; C Kılıç; M M Oren; M A Karan
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

7.  Comparing SARC-F with SARC-CalF to Screen Sarcopenia in Community Living Older Adults.

Authors:  G Bahat; M M Oren; O Yilmaz; C Kılıç; K Aydin; M A Karan
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

8.  Translation, Adaptation and Validation of Rapid Geriatric Assessment to the Brazilian context.

Authors:  F de Souza Orlandi; R Brochine Lanzotti; J Gomes Duarte; H Novais Mansur; M S Zazzetta; S C Iost Pavarini; M R Cominetti; S Matumoto
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

9.  Myopenia and precision (P4) medicine.

Authors:  John E Morley; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-09-24       Impact factor: 12.910

10.  Impact of COVID-19 on nutritional status during the first wave of the pandemic.

Authors:  Analía Ramos; Clara Joaquin; Mireia Ros; Mariona Martin; Montserrat Cachero; María Sospedra; Eva Martínez; José Manuel Sánchez Migallón; María-José Sendrós; Berta Soldevila; Manel Puig-Domingo
Journal:  Clin Nutr       Date:  2021-05-08       Impact factor: 7.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.